Brief: Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda
18/10/2025 15:30
Oct 18 (Reuters) - PFIZER: CO & ASTELLAS ANNOUNCE POSITIVE RESULTS FROM PHASE 3EV-303 CLINICAL TRIAL FOR PADCEV IN COMBINATION WITH KEYTRUDA PFIZER: PADCEV PLUS KEYTRUDA CUTS RISK OF RECURRENCE, PROGRESSION OR DEATH BY 60% & RISK OF DEATH BY 50% FOR CERTAIN PATIENTS WITH BLADDER CANCER Source text: [ID:] Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn